Kalaris Therapeutics, Inc. Cash Flow Conversion Efficiency
Kalaris Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has a cash flow conversion efficiency ratio of -0.195x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.35 Million) by net assets ($68.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kalaris Therapeutics, Inc. (2018–2025)
Cash flow conversion efficiency of Kalaris Therapeutics, Inc. from 2018 to 2025. This chart illustrates how Kalaris Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kalaris Therapeutics, Inc. (KLRS) share price today for real-time trading data and today's change.
Kalaris Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Kalaris Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kalaris Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see KLRS company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energous Corporation
NASDAQ:WATT
|
-0.132x |
|
A.J. Plast Public Company Limited
BK:AJ
|
0.107x |
|
Primotec Group Ltd
TA:PRMG
|
0.071x |
|
Nuveen New York Select Tax-Free Income Portfolio
NYSE:NXN
|
N/A |
|
Loyal Metals Ltd
AU:LLM
|
-0.034x |
|
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
|
-0.141x |
|
Elsoft Research Bhd
KLSE:0090
|
0.003x |
|
Lake Resources N.L.
AU:LKE
|
-0.064x |
Annual Cash Flow Conversion Efficiency for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kalaris Therapeutics, Inc. from 2018 to 2025. Review how much free cash does Kalaris Therapeutics, Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.81 Million | $-42.98 Million | -0.545x | +8.74% |
| 2024-12-31 | $113.31 Million | $-67.70 Million | -0.598x | -290.34% |
| 2023-12-31 | $-45.02 Million | $-14.13 Million | 0.314x | -2.82% |
| 2022-12-31 | $-30.27 Million | $-9.78 Million | 0.323x | +168.44% |
| 2021-12-31 | $225.27 Million | $-106.32 Million | -0.472x | -174.02% |
| 2020-12-31 | $353.06 Million | $-60.81 Million | -0.172x | -3.94% |
| 2019-12-31 | $121.62 Million | $-20.16 Million | -0.166x | -284.07% |
| 2018-12-31 | $21.58 Million | $1.94 Million | 0.090x | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more